Drug withdrawal and rebound hypertension: Differential action of the central antihypertensive drugs moxonidine and clonidine

Cardiovascular Drugs and Therapy

Volumn 10, Issue SUPPL. 1, 1996, Pages 251-262

  Rupp, Heinz ^a,b   Maisch, Bernhard ^a   Brilla, Christian G ^a  

^a UNIVERSITY OF TÜBINGEN   (Germany)

^b PHILIPPS UNIVERSITY MARBURG   (Germany)

Author keywords

Alpha2 receptor; Clonidine; Hypertension; Imidazoline I1 receptor; Moxonidine; Rebound

Indexed keywords

ALPHA 2 ADRENERGIC RECEPTOR; ANTIHYPERTENSIVE AGENT; CLONIDINE; IMIDAZOLINE RECEPTOR; MOXONIDINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIHYPERTENSIVE ACTIVITY; BODY WEIGHT; CALORIC INTAKE; CONFERENCE PAPER; CONTROLLED STUDY; DIASTOLIC BLOOD PRESSURE; DRUG WITHDRAWAL; HEART RATE; HYPERTENSION; MALE; NERVE CONDUCTION; NONHUMAN; OBESITY; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RAT; REBOUND; SPONTANEOUSLY HYPERTENSIVE RAT; SYMPATHETIC TONE; SYSTOLIC BLOOD PRESSURE; TELEMETRY; VAGUS NERVE;

ANIMALS; ANTIHYPERTENSIVE AGENTS; BLOOD PRESSURE; CLONIDINE; HEART RATE; HYPERTENSION; IMIDAZOLES; RATS; RATS, INBRED SHR; RATS, WISTAR; SUBSTANCE WITHDRAWAL SYNDROME; TELEMETRY;

EID: 0029952590     PISSN: 09203206     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF00120495     Document Type: Conference Paper

References (30)

1. Perry IJ, Whincup PH, Shaper AG. Environmental factors in the development of essential hypertension. Br Med Bull 1994;50:246-259.
2. Rupp H, Jacob R. Excess catecholamines and the metabolic syndrome: Should central imidazoline receptors be a therapeutic target? Med Hypotheses 1995;44:217-225.
3. Dhalla NS, Elimban V, Rupp H, Takeda N, Nagano M. Role of calcium in cardiac cell damage and dysfunction. In: Sperelakis N, ed. Physiology and Pathophysiology of the Heart, 3rd ed. Boston: Kluwer Academic, 1995:605-618.
4. Rupp H, Dhalla KS, Dhalla NS. Mechanisms of cardiac cell damage due to catecholamines: Significance of drugs regulating central sympathetic outflow. J Cardiovasc Pharmacol 1994;24(Suppl 1):S16-S24.
5. Hoffman BB, Lefkowitz RJ. Catecholamines and sympathomimetic drugs. In: Goodman Gilman A, Rail TW, Nies AS, Taylor P, eds. The Pharmacological Basis of Therapeutics. New York: Pergamon Press, 1990:187-220.
6. van Zwieten PA. The central action of antihypertensive drugs, mediated via central alpha-receptors. J Pharm Pharmacol 1973;25:89-95.
7. van Zwieten PA. Pharmacology of centrally acting hypotensive drugs. Br J Clin Pharmacol 1980;10:13S-20S.
8. Kobinger W. Central alpha-adrenergic systems as targets for hypotensive drugs. Rev Physiol Biochem Pharmacol 1978;81:40-100.
9. 1-imidazoline and alpha 2-adrenergic receptors in the antihypertensive responses evoked by central administration of clonidine analogs in conscious spontaneously hypertensive rats. J Pharmacol Exp Ther 1995;273: 1162-1171.
10. Reis DJ. The rostral ventrolateral medulla: A target of therapy for hypertension. Cardiovasc Risk Factors 1995; 5(Suppl 1):11-18.
11. 1-imidazoline against. Cardiovasc Drugs Ther 1994;8(Suppl 1):27-41.
12. Rupp H, Turcani M, Jacob R. Caloric intake and radiotelemetrically assessed high blood pressure. I. Effect of the centrally acting antihypertensive drug moxonidine. Pharm Pharmacol Lett 1993;3:103-106.
13. Goldberg AD, Raftery EB, Wilkinson PR. The over-shoot phenomenon on withdrawal of clonidine therapy. Postgrad Med J 1976;52(Suppl 7):128-134.
14. Reid JL, Dargie HJ, Davies DS, Wing LMH, Hamilton CA, Dollery CT. Clonidine withdrawal in hypertension. Changes in blood-pressure and plasma and urinary noradrenaline. Lancet 1977;1977:1171-1174.
15. Geyskes GG, Boer P, Dorhout Mees EJ. Clonidine withdrawal. Mechanism and frequency of rebound hypertension. Br J Clin Pharmacol 1979;7:55-62.
16. Weber MA. Discontinuation syndrome following cessation of treatment with clonidine and other antihypertensive agents. J Cardiovasc Pharmacol 1980;2(Suppl 1):S73-S89.
17. de La Coussaye JE, Eledjam JJ, Bassoul B, Bruelle P, Lefrant JY, Peray PA, et al. Receptor mechanisms for clonidine reversal of bupivacaine-induced impairment of ventricular conduction in pentobarbital-anesthetized dogs. Anesth Analg 1994;78:624-637.
18. Fujiwara T, Chiba S. Vascular responsiveness of rabbit common carotid, renal and femoral arteries to alpha-adrenoceptor agonists. Jpn J Pharmacol 1993;61:171-176.
19. Freedman RR, Moten M, Migaly P, Mayes M. Cold-induced potentiation of alpha 2-adrenergic vasoconstriction in primary Raynaud's disease. Arthritis Rheum 1993;36:685-690.
20. Scholtysik G, Jerie P, Picard CW. Guanfacine. In: Scriabine A, ed. Pharmacology of Antihypertensive Drugs. New York: Raven Press, 1980:79-98.
21. Holmes B, Brogden RN, Heel RC, Speight TM, Avery GS. Guanabenz. A review of its pharmacodynamic properties and therapeutic efficacy in hypertension. Drugs 1983;26: 212-229.
22. 1-imidazoline-receptor agonists in the treatment of hypertension: An appraisal of clinical experience. J Cardiovasc Pharmacol 1994;24(Suppl 1): S39-48.
23. Kraft K, Vetter H. Twenty-four-hour blood pressure profiles in patients with mild-to-moderate hypertension: Moxonidine versus captopril. J Cardiovasc Pharmacol 1994; 24(Suppl 1):S29-33.
24. 1-imidazoline agonist moxonidine administered into the rostral ventrolateral medulla. J Cardiovasc Pharmacol 1992:20(Suppl 4):S11-S15.
25. Mallard NJ, Hudson AL, Nutt DJ. Characterization and autoradiographical localization of non-adrenoceptor idazoxan binding sites in the rat brain. Br J Pharmacol 1992; 106:1019-1027.
26. Bjorntorp P. Treatment of obesity. Int J Obes Relat Metab Disord 1992;16(Suppl 3):S81-4.
27. Blundell J. Pharmacological approaches to appetite suppression. Trends Pharmacol Sci 1991;12:147-157.
28. Prichard BNC. Clinical experience with moxonidine. Cardiovasc Drugs Ther 1994;8(Suppl 1):49-58.
29. Harron DWG. Distinctive features of rilmenidine possibly related to its selectivity for imidazoline receptors. Am J Hypertens 1992;5:91S-98S.
30. Kaan EC, Bruckner R, Frohly P, Tulp M, Schäfer SG, Ziegler D. Effects of agmatine and moxonidine on glucose metabolism: An integrated approach towards pathophysiological mechanisms in cardiovascular metabolic disorder. Cardiovasc Risk Factors 1995;5:19-27.